Achaogen Inc. (AKAO) and Zosano Pharma Corporation (NASDAQ:ZSAN) Contrasting side by side

Achaogen Inc. (NASDAQ:AKAO) and Zosano Pharma Corporation (NASDAQ:ZSAN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achaogen Inc. 8.57M 7.64 175.37M -3.96 0.00
Zosano Pharma Corporation N/A 0.00 32.70M -9.39 0.00

Demonstrates Achaogen Inc. and Zosano Pharma Corporation earnings per share (EPS), top-line revenue and valuation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Achaogen Inc. -2,046.32% -227.2% -113.1%
Zosano Pharma Corporation 0.00% -185.2% -116.3%

Risk and Volatility

Achaogen Inc. has a beta of 0.56 and its 44.00% less volatile than S&P 500. Zosano Pharma Corporation on the other hand, has 1.82 beta which makes it 82.00% more volatile compared to S&P 500.


Achaogen Inc.’s Current Ratio is 2.5 while its Quick Ratio is 2.5. On the competitive side is, Zosano Pharma Corporation which has a 5.4 Current Ratio and a 5.4 Quick Ratio. Zosano Pharma Corporation is better positioned to pay off short and long-term obligations compared to Achaogen Inc.

Analyst Ratings

Recommendations and Ratings for Achaogen Inc. and Zosano Pharma Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Achaogen Inc. 0 6 0 2.00
Zosano Pharma Corporation 0 0 0 0.00

The upside potential is 111.27% for Achaogen Inc. with consensus price target of $3.

Institutional and Insider Ownership

Institutional investors held 50.5% of Achaogen Inc. shares and 59.7% of Zosano Pharma Corporation shares. Insiders held 19.4% of Achaogen Inc. shares. Comparatively, insiders own roughly 1.97% of Zosano Pharma Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achaogen Inc. 4.35% -45.45% -65.15% -86.06% -83.95% -84.36%
Zosano Pharma Corporation -3.74% -9.32% -7.93% -20.18% -68.48% -65.38%

For the past year Achaogen Inc.’s stock price has bigger decline than Zosano Pharma Corporation.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.